Asian Journal of Research in Dermatological Science

Evaluation of Quality of Life in Patients with Melasma Using MELASQOL Scale

Vaishnavi G. Hegde *

Department of Pharmacy Practice, Nargund College of Pharmacy, Bengaluru, Karnataka, India.

Amburaj E.

Department of Pharmacy Practice, Nargund College of Pharmacy, Bengaluru, Karnataka, India.

Binod Kumar Mahato

Department of Pharmacy Practice, Nargund College of Pharmacy, Bengaluru, Karnataka, India.

*Author to whom correspondence should be addressed.

---

Abstract

Aim: The objective of this study was to assess the quality of life in individuals with Melasma through the utilization of the MELASQOL scale. Additionally, the study aimed to investigate the correlation between the MASI score, duration of the disease, Melasma distribution pattern, and age of onset concerning the MELASQOL scale.

Study Design: A prospective cross-sectional study.

Place and Duration of Study: Tertiary care hospital, Bengaluru between January 2023 to June 2023.

Methodology: A total of 163 participants within the age range of 18 to 65 years, meeting the inclusion criteria, completed the MELASQOL questionnaires, and their corresponding MASI scores were subsequently determined.

Results: In this study with 163 subjects (11.65% males, 88.34% females), Melasma predominantly affected the 26-45 age group. Most subjects had Malar-type Melasma (69.3%), and common predisposing factors included family history (39.8%), 18(12.5%) female subjects having a history of oral contraceptives, and 13(9.02%) female subjects having a history of PCOD/PCOS. The mean MELASQOL was 57.128±11.95, and it was not statistically correlated with the MASI score (P=0.528 ρ= -0.0535) or distribution pattern (P=0.143 ρ= - 0.1321). Additionally, there was no significant correlation between age of onset and disease duration (P=0.4606, ρ= -0.066 and P=0.628, ρ= -0.068, respectively.

Conclusion: Melasma profoundly affects patients' quality of life, emphasizing the imperative to address psychological well-being alongside physical symptoms. Implementing the MELASQOL questionnaire and recommending follow-up counseling can enhance the management and overall well-being of melasma patients.

Keywords: Melasma, quality of life, MELASQOL, MASI score

---

---

---

References

Bandyopadhyay D. Topical treatment of melasma. Indian J Dermatol. 2009;54(4): 303–309.

Aishwarya K, Bhagwat PV, John N. Current concepts in melasma - a review article. J Skin Sex Transm Dis. 2020; 2:1317.

Mpofana N, Paulse M, Gqaleni N, Makgobole MU, Pillay P, Hussein A, Dlova NC. The Effect of melasma on the quality of life in people with darker skin types living in Durban, South Africa. Int J Environ Res Public Health. 2023; 20(22):7068.

DOI:10.3390/ijerph20227068.

PMID: 37998299; PMCID: PMC10671852.

Sarkar R, Arora P, Garg VK, Sonthalia S, Gokhale N. Melasma update. Indian Dermatol Online J. 2014;5(4): 426-35.

DOI:10.4103/2229-5178.142484.

PMID: 25396123; PMCID: PMC4228635.

Sanchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sanchez JL, Mihm MC Jr. Melasma: A clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol. 1981;4(6): 698-710.

DOI:10.1016/s0190-9622(81)70071-9.

PMID: 6787100.

Sarkar R, Ailawadi P, Garg S. Melasma in Men: A Review of Clinical, Etiological, and Management Issues. J Clin Aesthet Dermatol. 2018;11(2):53-59.

Epub;2018. PMID: 29552277;

PMCID: PMC5843363.

Lee A. Recent progress in Melasma Pathogenesis. Pigment cell & Melanoma Research. 2015;28(6):648– 60.

DOI:10.1111/pcmr.12404.

Achar A, Rathi SK. Melasma: A clinical-epidemiological study of 312 cases. Indian J Dermatol. 2011;56(4): 380-2.

DOI: 10.4103/0019-5154.84722.

PMID: 21965843; PMCID: PMC3178998.

Kimbrough-Green CK, Griffiths CE, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, Ellis CN, Voorhees JJ. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch Dermatol. 1994;130(6):727-33.

PMID: 8002642.

Handel AC, Miot LD, Miot HA. Melasma: A clinical and epidemiological review. A Bras Dermatol. 2014;89(5):771-82.

DOI: 10.1590/abd1806-4841.20143063.

PMID: 25184917; PMCID: PMC4155956.

Rendon MI. Hyperpigmentation disorders in hispanic population in the United States. J Drugs Dermatol. 2019;18(3):s112-114.

PMID: 30909362.

Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, Feldman SR, Chren MM. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;149(3):572-7.

DOI: 10.1046/j.1365-2133.2003.05419.x.

PMID: 14510991.

Sharma A, Bajpai S, Paghdar D, et al. Impact of melasma on quality of life in Indian patients. Indian J Dermatol. 2017;62(4):395–399.

Sarkar R, Garg S, Dominguez A, Balakrishnan R, Jain RK, Pandya AG. Development and validation of a Hindi language health-related quality of life questionnaire for melasma in Indian patients. Indian J Dermatol Venereol Leprol. 2016;82(1):16- 22.

DOI: 10.4103/0378-6323.168937.

PMID: 26728805.

Harumi O, Goh CL. The Effect of Melasma on the quality of life in a sample of women living in Singapore. J Clin Aesthet Dermatol. 2016;9(1):21-4.

PMID: 26962388; PMCID: PMC4756868

Misery L, Schmitt AM, Boussetta S, Rahhali N, Taieb C. Melasma: a measure of the impact on quality of life using the French version of MELASQOL after cross-cultural adaptation. Acta Derm Venereol. 2010;90(3):331-2. DOI: 10.2340/00015555-0837. PMID: 20526570.

Jiang J, Akinseye O, Tovar-Garza A, Pandya AG. The effect of melasma on self- esteem: A pilot study. Int J Womens Dermatol. 2017;4(1):38-42. DOI:10.1016/j.ijwd.2017.11.003. PMID: 29872675; PMCID:PMC5986109.